CXCL10 and acute myeloid leukemia: Additionally, the study showed that the high expressions of CCL3, CCL4 and CXCL10, independent of sex, age, FAB phenotype, patient status and risk molecular, were associated with the poor outcome of AML patients, suggesting they are valuable for AML prognosis.